BIOLINERX LTD/S (NASDAQ:BLRX) shares saw unusually-high trading volume on Thursday . Approximately 1,480,208 shares were traded during mid-day trading, an increase of 129% from the previous session’s volume of 646,678 shares.The stock last traded at $0.67 and had previously closed at $0.66.
BLRX has been the subject of a number of recent analyst reports. Maxim Group restated a “buy” rating and issued a $2.00 price objective on shares of BIOLINERX LTD/S in a research report on Monday, August 13th. HC Wainwright set a $4.00 price objective on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Tuesday, August 14th. Zacks Investment Research upgraded shares of BIOLINERX LTD/S from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Thursday, August 16th. ValuEngine upgraded shares of BIOLINERX LTD/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 4th. Finally, Oppenheimer set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Friday, November 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $2.50.
The stock has a market cap of $70.39 million, a P/E ratio of -2.49 and a beta of 0.84.
BIOLINERX LTD/S (NASDAQ:BLRX) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). As a group, sell-side analysts anticipate that BIOLINERX LTD/S will post -0.22 earnings per share for the current year.
An institutional investor recently bought a new position in BIOLINERX LTD/S stock. Fosun International Ltd bought a new stake in BIOLINERX LTD/S (NASDAQ:BLRX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned approximately 1.27% of BIOLINERX LTD/S at the end of the most recent quarter. 36.01% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “BIOLINERX LTD/S (BLRX) Sees Strong Trading Volume” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/12/07/biolinerx-ltd-s-blrx-sees-strong-trading-volume.html.
BIOLINERX LTD/S Company Profile (NASDAQ:BLRX)
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: How analysts view the yield curve
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.